Molecular Sciences Comparative Analysis of Human Mesenchymal Stem Cells from Bone Marrow, Adipose Tissue, and Umbilical Cord Blood as Sources of Cell Therapy

Various source-derived mesenchymal stem cells (MSCs) have been considered for cell therapeutics in incurable diseases. To characterize MSCs from different sources, we compared human bone marrow (BM), adipose tissue (AT), and umbilical cord blood-derived MSCs (UCB-MSCs) for surface antigen expression, differentiation ability, proliferation capacity, clonality, tolerance for aging, and paracrine activity. Although MSCs from different tissues have similar levels of surface antigen expression, immunosuppressive activity, and differentiation ability, UCB-MSCs had the highest rate of cell proliferation and clonality, and significantly lower expression of p53, p21, and p16, well known markers of senescence. Since paracrine action is the main action of MSCs, we examined the anti-inflammatory activity of each MSC under lipopolysaccharide (LPS)-induced inflammation. Co-culture of UCB-MSCs with LPS-treated rat alveolar macrophage, reduced expression of inflammatory cytokines including interleukin-1α (IL-1α), IL-6, and IL-8 via angiopoietin-1 (Ang-1). Using recombinant Ang-1 as potential soluble paracrine factor or its small interference RNA (siRNA), we found that Ang-1 secretion was responsible for this beneficial effect in part by preventing inflammation. Our results demonstrate that primitive UCB-MSCs have biological advantages in comparison to adult sources, making UCB-MSCs a useful model for clinical applications of cell therapy.

[1]  J. Gamble,et al.  Angiopoietin-1 Is an Antipermeability and Anti-Inflammatory Agent In Vitro and Targets Cell Junctions , 2000, Circulation research.

[2]  O. Lee,et al.  Isolation of multipotent mesenchymal stem cells from umbilical cord blood. , 2004, Blood.

[3]  John M Sedivy,et al.  Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). , 2004, Molecular cell.

[4]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.

[5]  Hermann Eichler,et al.  Comparative Analysis of Mesenchymal Stem Cells from Bone Marrow, Umbilical Cord Blood, or Adipose Tissue , 2006, Stem cells.

[6]  A. Caplan,et al.  Mesenchymal stem cells as trophic mediators , 2006, Journal of cellular biochemistry.

[7]  Qin-jun Zhao,et al.  Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. , 2006, Haematologica.

[8]  L. Ortiz,et al.  Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury , 2007, Proceedings of the National Academy of Sciences.

[9]  L. Fouillard,et al.  Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. , 2006, Gene expression.

[10]  J. Toguchida,et al.  Expression of the p16INK4A Gene Is Associated Closely with Senescence of Human Mesenchymal Stem Cells and Is Potentially Silenced by DNA Methylation During In Vitro Expansion , 2007, Stem cells.

[11]  A. Caplan.  Adult mesenchymal stem cells for tissue engineering versus regenerative medicine , 2007, Journal of cellular physiology.

[12]  D. Stewart,et al.  Competing Interests: This work was , 2022 .

[13]  Andreas Reinisch,et al.  Humanized system to propagate cord blood-derived multipotent mesenchymal stromal cells for clinical application. , 2007, Regenerative medicine.

[14]  Catherine M. Verfaillie,et al.  Pluripotency of mesenchymal stem cells derived from adult marrow , 2007, Nature.

[15]  W. Liu,et al.  BMC Cell Biology BioMed Central , 2007 .

[16]  Jae Kwon Lee,et al.  Immunological properties of umbilical cord blood-derived mesenchymal stromal cells. , 2008, Cellular immunology.

[17]  L. He,et al.  Mesenchymal stem cell‐based angiopoietin‐1 gene therapy for acute lung injury induced by lipopolysaccharide in mice , 2007, The Journal of pathology.

[18]  V. Beneš,et al.  Replicative Senescence of Mesenchymal Stem Cells: A Continuous and Organized Process , 2008, PloS one.

[19]  H. Lim,et al.  Human amnion‐derived mesenchymal stem cells are a potential source for uterine stem cell therapy , 2008, Cell proliferation.

[20]  Seung-Baik Kang,et al.  Fetal mesenchymal stem cells derived from human umbilical cord sustain primitive characteristics during extensive expansion , 2008, Cell and Tissue Research.

[21]  A. Cometa,et al.  Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors , 2009, Haematologica.

[22]  J. Kim,et al.  Overexpression of CXC chemokine receptors is required for the superior glioma-tracking property of umbilical cord blood-derived mesenchymal stem cells. , 2009, Stem cells and development.

[23]  Z. Cui,et al.  Optimization of primary culture condition for mesenchymal stem cells derived from umbilical cord blood with factorial design , 2009, Biotechnology progress.

[24]  M. Krampera,et al.  Human bone marrow and adipose tissue mesenchymal stem cells: a user's guide. , 2010, Stem cells and development.

[25]  H. Zhang,et al.  Replicative senescence of human bone marrow and umbilical cord derived mesenchymal stem cells and their differentiation to adipocytes and osteoblasts , 2011, Molecular Biology Reports.

[26]  Young-ho Kim.  Mesenchymal stem cells cultured under hypoxia escape from senescence via down-regulation of p16 and extracellular signal regulated kinase , 2010 .

[27]  S. Kim,et al.  GD2 expression is closely associated with neuronal differentiation of human umbilical cord blood-derived mesenchymal stem cells , 2010, Cellular and Molecular Life Sciences.

[28]  J. Chang,et al.  Galectin‐3 secreted by human umbilical cord blood‐derived mesenchymal stem cells reduces amyloid‐β42 neurotoxicity in vitro , 2010, FEBS letters.

[29]  C. De Bari,et al.  The regulation of differentiation in mesenchymal stem cells. , 2010, Human gene therapy.

[30]  Cláudia Lobato da Silva,et al.  Ex vivo expansion of human mesenchymal stem cells: A more effective cell proliferation kinetics and metabolism under hypoxia , 2009, Journal of cellular physiology.

[31]  P. Pelosi,et al.  Mechanisms of cellular therapy in respiratory diseases , 2011, Intensive Care Medicine.

[32]  S. Laitinen,et al.  The isolation and culture of human cord blood-derived mesenchymal stem cells under low oxygen conditions. , 2011, Methods in molecular biology.

[33]  A. Caplan,et al.  Mesenchymal stem cells: mechanisms of inflammation. , 2011, Annual review of pathology.

[34]  H. Satoh,et al.  Isolation and characterization of mesenchymal stem cells from human umbilical cord blood: Reevaluation of critical factors for successful isolation and high ability to proliferate and differentiate to chondrocytes as compared to mesenchymal stem cells from bone marrow and adipose tissue , 2011, Journal of cellular biochemistry.

[35]  S. Böhm,et al.  Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC , 2011, Cell Communication and Signaling.

[36]  Y. Chang,et al.  Intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells dose-dependently attenuates hyperoxia-induced lung injury in neonatal rats. , 2011, Cell transplantation.

[37]  J. Kim,et al.  CXC chemokine receptor 1 enhances the ability of human umbilical cord blood-derived mesenchymal stem cells to migrate toward gliomas. , 2011, Biochemical and biophysical research communications.

[38]  M. Matthay,et al.  Concise Review: Mesenchymal Stem Cells for Acute Lung Injury: Role of Paracrine Soluble Factors , 2011, Stem cells.

[39]  M. B. Eslaminejad,et al.  Isolation, characterization and comparative differentiation of human dental pulp stem cells derived from permanent teeth by using two different methods. , 2012, Journal of visualized experiments : JoVE.

[40]  E. Bünemann,et al.  Distinct differentiation potential of "MSC" derived from cord blood and umbilical cord: are cord-derived cells true mesenchymal stromal cells? , 2012, Stem cells and development.

[41]  D. Na,et al.  Soluble intracellular adhesion molecule-1 secreted by human umbilical cord blood-derived mesenchymal stem cell reduces amyloid-β plaques , 2011, Cell Death and Differentiation.

[42]  S. Karaman,et al.  Donor age and long-term culture affect differentiation and proliferation of human bone marrow mesenchymal stem cells , 2012, Annals of Hematology.

[43]  Yongsung Kim,et al.  Comparison of mesenchymal stem cells derived from fat, bone marrow, Wharton's jelly, and umbilical cord blood for treating spinal cord injuries in dogs. , 2012, The Journal of veterinary medical science.

[44]  C. V. van Blitterswijk,et al.  Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements. , 2012, Tissue engineering. Part B, Reviews.

[45]  M. Reinders,et al.  A Mesenchymal Stromal Cell Gene Signature for Donor Age , 2012, PloS one.